Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02155595 · ClinicalTrials.gov registry record
Pathogenesis of Atypical Femur Fractures on Long Term Bisphosphonate Therapy
A clinical trial, sponsored by Henry Ford Health System.
- Completed
- Registry status
- 738
- Enrollment target
NCT02155595 is a clinical trial that has completed, run by Henry Ford Health System. The registered enrollment target is 738 participants.
The verdict
NCT02155595 has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- 738 participants
- Enrollment target
Study Summary
The purpose of this protocol is to determine the risk of atypical femoral shaft (thigh bone) fractures after long term fracture prevention therapy with a class of drugs called "bisphosphonates", colloquially referred to as Alendronate, risedronate, Ibandronate, and Zoledronate. In addition, the study is designed to find out which patient is most likely to develop this potential life changing complication and why. Finally, the results of this study will help clinicians to better understand the reason and thus tailor patient specific treatments…i.e., "the right treatment for the right patient for right duration."
Interventions
- OTHER 500 without BP treatment
- OTHER 500 with BP treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 738 participants |
| Start Date | 2014-05 |
| Est. Completion | 2018-08-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02155595
The ClinicalTrials.gov registry entry for NCT02155595 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 738 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 500 without BP treatment is the first listed.
NCT02155595 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02155595 about?
NCT02155595 is a clinical study titled "Pathogenesis of Atypical Femur Fractures on Long Term Bisphosphonate Therapy". The purpose of this protocol is to determine the risk of atypical femoral shaft (thigh bone) fractures after long term fracture prevention therapy with a class of drugs called "bisphosphonates", colloquially referred to as Alendronate, risedronate, Ibandronate, and Zoledronate. In addition, the stu...
What is the current status of trial NCT02155595?
This trial is currently completed. The enrollment target is 738 participants. The study started on 2014-05. Estimated completion is 2018-08-31.
What interventions are being tested in trial NCT02155595?
The interventions under investigation include: 500 without BP treatment (OTHER), 500 with BP treatment (OTHER).
Who is sponsoring clinical trial NCT02155595?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.